Enrollment was terminated in June 2008 due to market withdrawal of the NexStent Carotid Stent System.

The primary objective of the SONOMA Registry is to confirm the safety of the NexStent® Carotid Stent System and FilterWire EZ™ Embolic Protection System in routine clinical practice and to identify rare or unanticipated device-related events that might occur.

The SONOMA Registry will enroll approximately 300 subjects at a maximum at 78 study centers.

Inclusion Criteria:

• Candidates must be indicated for carotid stent placement as per NexStent Carotid Stent labeling located in the Directions for Use (DFU).

Exclusion Criteria:

• Subjects with contraindications as outlined in the DFU should be excluded from this registry.

The disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor can require changes to the communication to remove any confidential information or other proprietary information of Sponsor.